Share on StockTwits

Momenta Pharmaceuticals (NASDAQ:MNTA) Director Bennett M. Shapiro sold 3,721 shares of Momenta Pharmaceuticals stock on the open market in a transaction that occurred on Wednesday, August 13th. The stock was sold at an average price of $12.00, for a total transaction of $44,652.00. Following the transaction, the director now directly owns 8,279 shares in the company, valued at approximately $99,348. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

A number of research firms have recently commented on MNTA. Analysts at Maxim Group initiated coverage on shares of Momenta Pharmaceuticals in a research note on Thursday, June 5th. They set a “buy” rating and a $17.00 price target on the stock. Analysts at Goldman Sachs initiated coverage on shares of Momenta Pharmaceuticals in a research note on Monday, June 2nd. They set a “buy” rating and a $19.00 price target on the stock. One investment analyst has rated the stock with a sell rating and six have issued a buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $19.20.

Momenta Pharmaceuticals (NASDAQ:MNTA) traded down 0.26% on Friday, hitting $11.65. 188,459 shares of the company’s stock traded hands. Momenta Pharmaceuticals has a 52-week low of $9.85 and a 52-week high of $19.90. The stock’s 50-day moving average is $11.32 and its 200-day moving average is $13.07. The company’s market cap is $599.8 million.

Momenta Pharmaceuticals (NASDAQ:MNTA) last posted its quarterly earnings results on Thursday, July 31st. The company reported ($0.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.46) by $0.05. The company had revenue of $11.00 million for the quarter, compared to the consensus estimate of $11.22 million. During the same quarter in the previous year, the company posted ($0.57) earnings per share. The company’s revenue for the quarter was up 151.1% on a year-over-year basis. On average, analysts predict that Momenta Pharmaceuticals will post $-1.14 earnings per share for the current fiscal year.

Momenta Pharmaceuticals, Inc (NASDAQ:MNTA) is a biotechnology company specializing in the characterization and process engineering of complex molecules.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.